Cargando…
Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157361/ https://www.ncbi.nlm.nih.gov/pubmed/35640929 http://dx.doi.org/10.1136/jitc-2022-004965 |
_version_ | 1784718622528110592 |
---|---|
author | Zheng, Jieling Zhang, Bin |
author_facet | Zheng, Jieling Zhang, Bin |
author_sort | Zheng, Jieling |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9157361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91573612022-06-16 Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al Zheng, Jieling Zhang, Bin J Immunother Cancer Letter BMJ Publishing Group 2022-05-31 /pmc/articles/PMC9157361/ /pubmed/35640929 http://dx.doi.org/10.1136/jitc-2022-004965 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Letter Zheng, Jieling Zhang, Bin Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al |
title | Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
|
title_full | Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
|
title_fullStr | Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
|
title_full_unstemmed | Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
|
title_short | Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
|
title_sort | correspondence on 'novel imaging biomarkers predict outcomes in stage iii unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by jazieh et al |
topic | Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157361/ https://www.ncbi.nlm.nih.gov/pubmed/35640929 http://dx.doi.org/10.1136/jitc-2022-004965 |
work_keys_str_mv | AT zhengjieling correspondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyjaziehetal AT zhangbin correspondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyjaziehetal |